<DOC>
	<DOCNO>NCT02029443</DOCNO>
	<brief_summary>This study evaluate safety efficacy new Bruton tyrosine kinase ( Btk ) inhibitor , acalabrutinib , treatment chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL )</brief_summary>
	<brief_title>ACP-196 ( Acalabrutinib ) , Novel Bruton Tyrosine Kinase ( Btk ) Inhibitor , Treatment Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<criteria>Men woman ≥ 18 year age confirm diagnosis CLL/SLL , relapse , refractory , ≥ 2 previous treatment CLL/SLL ; however , subject 17p deletion eligible relapse , refractory , 1 prior treatment CLL/SLL . Treatment Naive : ) want receive chemoimmunotherapy b ) comorbidities would preclude chemoimmunotherapy . Richter 's Syndrome Prolymphocytic Leukemia Transformation : biopsy proven DLBCL Richter 's transformation prolymphocytic leukemia transformation . Subjects diagnose measurable CLL/SLL . Subjects active disease meeting IWCLL 2008 publish criterion . ECOG performance status ≤ 2 . Agreement use contraception study 90 day last dose study drug sexually active able bear child . Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year . Note : case must discuss Medical Monitor . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism acalabrutinib , put study outcome undue risk . Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification , leave ventricular ejection fraction ( LVEF ) ≤ 40 % . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Any immunotherapy within 4 week first dose study drug . For subject recent chemotherapy experimental therapy first dose study drug must occur 5 time halflife agent ( ) . Relapsed , refractory , prior BTK inhibitor therapy . Central nervous system ( CNS ) involvement lymphoma Grade ≥ 2 toxicity ( alopecia ) continue prior anticancer therapy include radiation . Known history human immunodeficiency virus ( HIV ) active infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) uncontrolled active systemic infection . Major surgery within 4 week first dose study drug . ANC &lt; 0.75 x 109/L platelet count &lt; 50 x 109/L unless bone marrow involvement . Creatinine &gt; 1.5 x institutional upper limit normal ( ULN ) ; total bilirubin &gt; 1.5 x ULN ( unless due Gilbert 's disease ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3.0 x ULN unless disease relate . Serum amylase &gt; 1.5 x ULN serum lipase &gt; 1.5 x ULN . Significant screen ECG abnormality include leave bundle branch block , 2nd degree AV block type II , 3rd degree block , Grade 2 high bradycardia , QTc ≥ 480 ms. Cardiac troponin I cardiac troponin T level limit normal specified manufacturer . Lactating pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bruton 's tyrosine kinase inhibitor</keyword>
</DOC>